Propiedad y actividad de insiders de Arbutus Biopharma Corp (ABUS): operaciones de insiders, transacciones del Senado y la Cámara de EE. UU. y acciones en circulación. Sigue cómo operan la acción los directivos y los políticos.
Precio
| Precio | $5.05 |
| Capitalización | $998M |
| Bolsa | NASDAQ |
| País | US |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $23.4M | $54.3M | $36.9M | $31.8M | $52.3M | $109.3M | $30.8M | $26.3M | $36.3M | $18.0M |
| Inversiones a Corto | $107.1M | $72.1M | $87.7M | $59.0M | $71.0M | $46.0M | $116.1M | $99.7M | $86.3M | $73.5M |
| Cuentas por Cobrar | $694000 | $870000 | $1.4M | $1.2M | $1.3M | $899000 | $1.4M | $1.8M | $2.4M | $1.7M |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $132.6M | $129.4M | $129.2M | $93.8M | $127.7M | $160.7M | $151.1M | $132.0M | $127.3M | $94.5M |
| Inmovilizado Material | $6.9M | $12.2M | $10.1M | $11.4M | $9.3M | $8.1M | $6.8M | $6.1M | $4.4M | $32000 |
| Fondo de Comercio | $24.4M | $24.4M | $22.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | $99.4M | $58.6M | $43.8M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $275.9M | $237.2M | $227.9M | $105.5M | $137.1M | $204.5M | $195.4M | $144.4M | $131.7M | $94.6M |
| Cuentas por Pagar | $3.2M | $2.0M | $3.2M | $2.4M | $3.0M | $3.2M | $3.5M | $3.2M | $2.3M | $1.2M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | $383000 | $372000 | 0 | $483000 | $547000 |
| Pasivos Corrientes | $10.6M | $11.9M | $11.2M | $7.8M | $9.5M | $11.2M | $32.9M | $22.5M | $15.6M | $6.0M |
| Deuda a Largo | $12.0M | $12.0M | 0 | 0 | $19.6M | $16.3M | $10.4M | $7.0M | $4.8M | $3.4M |
| Pasivos Totales | $72.9M | $54.7M | $27.7M | $32.8M | $35.1M | $35.0M | $58.6M | $38.4M | $34.3M | $18.0M |
| Reservas | -$651.1M | -$738.1M | -$805.2M | -$970.1M | -$1.05B | -$1.13B | -$1.20B | -$1.28B | -$1.35B | -$1.38B |
| Patrimonio Neto | $203.0M | $182.5M | $200.2M | $72.7M | $102.0M | $169.4M | $136.9M | $106.0M | $97.4M | $76.6M |
| Deuda Total | $12.0M | $12.0M | 0 | $3.4M | $22.5M | $18.9M | $12.6M | $8.7M | $6.1M | $4.2M |
| Deuda Neta | -$118.5M | -$114.4M | -$124.6M | -$87.5M | -$100.7M | -$136.4M | -$134.4M | -$117.3M | -$116.5M | -$87.3M |
| Capital Circulante | $122.0M | $117.5M | $118.0M | $86.0M | $118.2M | $149.4M | $118.3M | $109.5M | $111.7M | $88.5M |
Salud financiera
| Deuda / Patrimonio | 0.01 |
| Ratio corriente | 81.42 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 10.56 |
Rentabilidad
| Rentabilidad sobre capital | 90.98% |
| Rentabilidad sobre capital invertido | 54.29% |
| Rentabilidad sobre activos | 55.85% |
| Margen bruto | 99.98% |
| Margen operativo | 81.01% |
| Margen neto | 84.23% |
Empresas relacionadas: BCAX · EYPT · GHRS · KURA · NBTX · PROK · SEPN
Explorar sector: Healthcare · Biotechnology
Más secciones de ABUS: Resumen · Financieros · Valoración · Estadísticas · Estimaciones · Técnico · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones